期刊文献+

Effect of osteoprotegerin in combination with interleukin-6 on inhibition of osteoclast differentiation 被引量:9

Effect of osteoprotegerin in combination with interleukin-6 on inhibition of osteoclast differentiation
原文传递
导出
摘要 Objective: To observe the effect of recombinant interleukin-6 (IL-6) and osteoprotegerin (OPG) on inhibiting bone absorption induced by receptor activa- tor for nuclear factor- rB ligand (RANKL) in murine osteo- clast precursor cells (OCPs) model. Methods: RAW 264.7 cells were solely treated with 50 ng/ml RANKL for 1 day, and then they were divided into three groups: RANKL (control group), RANKL+IL-6 (IL-6 group) and RANKL+IL-6+OPG (combination group). These cells were harvested and investigated by means of HE stain- ing under light microscope after consecutive 9 days. Furthermore, staining tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells were detected by in- verted phase contrast microscope. The absorption pits of bone slices were observed under scanning electron microscope. Results: The number of mature osteoclast cells in control group was more than that in IL-6 alone or IL-6 com- bined with OPG group (P〈0.05). Interestingly, this experi- ment has also demonstrated that there was a large number of TRAP-positive multinucleated osteoclasts (more than 3 nuclei) and several bone absorption formation in the con- trol group, whereas the outcome was completely different in both IL-6 group and IL-6+OPG group (P〈0.05). Conclusion: IL-6 can suppress the differentiation of mature osteoclasts as directly adding it into the RAW 264.7 cells induced by 50 ng/ml RANKL, and further the effect of osteolysis is remarkably reduced. When treatment with IL- 6 combined with OPG, a more effective strategy for the treat- ment of osteoporosis is reached.
出处 《Chinese Journal of Traumatology》 CAS CSCD 2013年第5期277-280,共4页 中华创伤杂志(英文版)
关键词 OSTEOCLASTS OSTEOPOROSIS Osteopro- tegerin RANK ligand INTERLEUKIN-6 白细胞介素-6 细胞分化 IL-6 扫描电子显微 破骨细胞 HE染色 多核细胞 TRAP
  • 相关文献

参考文献2

二级参考文献19

  • 1Boyle WJ,Simonet WS,Lacey DL.Osteoclast differentiation and activation.Nature,2003,423:337-342.
  • 2Tsurukai T,Udagawa N,Matsuzaki K.Role of macrophagecolony stimulating factor and osteoclast differentiation factor in osteoclastogenesis.Bone Miner Metab,2000,12(18):177.
  • 3Lee SW,Kwak HB,Chung WJ,et al.Participation of protein kinase C β in osteoclast differentiation and function.Aethritis Rheum,2002,46(12):3121-313S.
  • 4Naoko Y,Tohru T,Haruyasu U,et al.Down-regulation of osteoprotegerin production in bone marrow macrophages by macrophage colony-stimulating factor.Cytokine,2005,31 (28):287-297.
  • 5Fukumoto S,Iwamoto T,Sakai E,et al.Current topics in pharmacological research on bone metabolism:osteoclast differentiation regulated by glycosphingolipids.J Pharmacol Sci,2006,100(3):195-200.
  • 6Hus H,Lacey D,Dunstan C,et al.Tumor necrosis receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.Proc Natl Acad Sci USA,1999,96:3540-3545.
  • 7Deal C. Potential new drug targets for osteoporosis. Nat Clin Pract Rheumatol, 2009,5 ( 3 ) : 174.
  • 8Faccio R,Takeshita S,Zallone A,et al. c-Fms and αvβ3 integrin collaborate during osteoclnst differentiation. J Clin Invest,2003, 111:749-758.
  • 9Wright HI,, McCarthy HS, Middleton J,et al. RANK/ RANKL and osteoprotegerin in bone biology and disease. Curt Rev Musculoskelet Med .2009.2( 1 ) :56-64.
  • 10Battaglino R,Kim D, Fu J, et al. c-myc is required for osteoclast differentiation. J Bone Miner Res,2002,17 (5) :763-773.

共引文献9

同被引文献75

引证文献9

二级引证文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部